Apollon Formularies names Dr Archibald McDonald as clinical trials director
Apollon Formularies PLC (AQSE:APOL) said it appointed Dr Archibald McDonald as its director of clinical trials.
McDonald is a surgeon and has served in various capacities throughout his 35-year tenure at the University of the West Indies, including as vice principal, head of the department of surgery, radiology, anesthesia and intensive care and as chief executive officer, the medical cannabis pharmaceutical company said in a statement.
McDonald has received a number of academic awards, including the vice chancellor's Award for Excellence in the category, Outstanding Service to the University Community; MAJ Award for Distinguished Service to the Medical Profession; JEMA Award for Establishment and Continuing Contribution to the Evolution of Emergency Medicine in Jamaica; and MAJ President's Award for Distinguished Service in the Field of Medical Education.
He is a Fellow of the Royal College of Surgeons of Edinburgh, Fellow of the American College of Surgeons and Member of the American College of Emergency Physicians.
He has published over 150 peer-reviewed scientific papers, abstracts, invited articles and book chapters and has lectured extensively for many years at international and national meetings of medical and professional societies.
McDonald will not be a member of the main board of Apollon.
"Professor McDonald is a highly respected surgeon and experienced research physician; Apollon is honored to have him join our team as director of clinical trials," said Apollon executive chairman and CEO Stephen D Barnhill.
"We are excited to immediately begin working with Dr McDonald to start human clinical trials to validate the success of our pre-clinical studies."
McDonald added: "I look forward to working with Dr Barnhill, a pioneer in using artificial intelligence in medical cannabis formulation development, and the Apollon medical team on initiating human clinical trials in Jamaica."
"If we achieve the same level of success in human clinical trials that was recently demonstrated in the independent, 3rd party pre-clinical studies, these products could greatly help cancer patients in Jamaica and internationally."< Back to News